A universal influenza vaccine in the pipeline |
Editorial
eMediNexus Coverage from: 
A universal influenza vaccine in the pipeline
Dr Sanjay Kalra, DM, Bharti Hospital, Karnal Immediate Past President, Endocrine Society of India,  08 June 2021
Coronavirus Live Count Map India

remove_red_eye 1611 Views
COVID-19 Vaccine Updates

Coronavirus Protocols

#Multispeciality

1 Read Comments                

The safety and immunogenicity of FluMos-v1, an experimental nanoparticle influenza vaccine developed to provide long-lasting protection against multiple flu virus strains, is being evaluated in a first-in-human, Phase 1 trial. Scientists from NIH’s National Institute of Allergy and Infectious Diseases (NIAID) developed FluMos-v1 to stimulate antibodies against multiple influenza virus strains by displaying part of the influenza virus hemagglutinin (HA) protein on self-assembling nanoparticle scaffolds. Similarities with available flu vaccines: FluMos-v1 vaccine is designed to elicit antibodies directed against the hemagglutinin protein from four different virus strains, two influenza type A strains of H1 and H3 subtype and two influenza type B strains.Dissimilarities with available flu vaccines: FluMos-v1 displays multiple copies of each of the four HA types. The 20 HA ep...
To Read or comment on this article,
create a free account.
Sign Up to instantly read 30000+ free Articles & 1000+ Case Studies
Create Account

Already registered?

Login Now